Paramyxoviridae Infections, Virus Diseases
Conditions
Keywords
Respiratory Tract Disease, Bovine, Chimeric Vaccine
Brief summary
Human parainfluenza viruses (HPIVs) are a major health concern in infants and young children under 5 years of age, causing serious respiratory tract disease. The purpose of this study is to test the safety of and immune response to a new HPIV vaccine in healthy infants, children, and adults.
Detailed description
HPIV type 3 (HPIV3) ranks second only to respiratory syncytial virus as the most common cause of bronchiolitis and pneumonia in infants less than 6 months of age. HPIV3 can cause severe disease in the first 2 years of life and is responsible for 11% of hospitalizations for respiratory diseases in children. This study will evaluate the safety and immunogenicity of a live, chimeric bovine/human, attenuated intranasal HPIV3 vaccine, rB/HPIV3. This vaccine combines modified human HPIV3 with a related, modified cow virus, bovine parainfluenza type 3 virus (BPIV3). Vaccinations will be given as nose drops to healthy adults, children seropositive for HPIV3, and infants and children seronegative for HPIV3. There are four groups in this study. Group 1 will consist of adults who will receive the higher dose of rB/HPIV3. Group 2 will consist of seropositive children who will be randomly assigned to receive the higher dose of rB/HPIV3 or placebo. Group 2 will not begin enrollment until the completion of Group 1 safety data review. Participants of both Groups 1 and 2 will be monitored for 10 days post vaccination for respiratory illness and for fever by self-reported temperature logs; these participants will be followed for a maximum of 28 days. Blood collection will occur at study entry and on Day 28; additional blood collection may occur up to 28 days prior to vaccination. Clinical assessments and nasal washes will occur at study entry and selected study visits. Group 1 participants will be contacted by phone on Day 180; Group 2 participants' parents or guardians will be contacted by phone on Days 1, 2, 8, 9, 11, and 180; study staff will ask about any illnesses or adverse events that may have occurred. Groups 3 and 4 will consist of seronegative infants and children. Group 3 will not begin enrollment until the completion of Group 2 safety data review. Children in Group 3 will be randomly assigned to receive the lower dose of rB/HPIV3 or placebo. Group 4 will not begin enrollment until the completion of Group 3 safety data review. Children in Group 4 will be randomly assigned to receive the higher dose of rB/HPIV3 or placebo. Participants of both Groups 3 and 4 will be monitored closely for 28 days postvaccination for respiratory illness and for fever by self-reported temperature logs; these participants will be followed for a maximum of 56 days. Blood collection will occur at study entry and on Day 56. Clinical assessments and nasal washes will occur at study entry and most study visits. Participants' parents or guardians will be contacted by phone periodically post vaccination; study staff will ask about any illnesses or adverse events they may have observed in their infants or children.
Interventions
BIOLOGICALrB/HPIV3
Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50
BIOLOGICALPlacebo
Placebo for rB/HPIV3 vaccine
Sponsors
Johns Hopkins Bloomberg School of Public Health
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to 49 Years
Healthy volunteers
Yes
Inclusion criteria
for Adult Participants: * Good general health * Available for the duration of the trial * Reachable by telephone for post-vaccination contact * Female participants willing to use acceptable methods of contraception Inclusion Criteria for Seropositive Child Participants: * Good general health and age-appropriate development, as determined by physical exam and medical history review * Seropositive for human parainfluenza type 3 virus (HPIV3), as defined by a serum hemagglutination-inhibition (HI) antibody titer of more than 1:8 * Available for the duration of the trial * Parent or guardian willing to provide informed consent * Parent or guardian reachable by telephone for post-vaccination contact Inclusion Criteria for Seronegative Infant and Child Participants: * Good general health and age-appropriate development, as determined by physical exam and medical history review * Seronegative for HPIV3, as defined by serum HI antibody titer of 1:8 or less within 28 days of first vaccination * Available for the duration of the trial * Parent or guardian willing to provide informed consent * Parent or guardian reachable by telephone for post-vaccination contact
Exclusion criteria
for Adult Participants: * Clinically significant neurologic, heart, lung, liver, rheumatologic, autoimmune, or kidney disease * Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the ability of the participant to understand and cooperate with the study * Medical, work-related, or family problems as a result of alcohol or illicit drug use in the 12 months prior to study entry * History of severe allergic reaction or anaphylaxis * Absence of spleen * Diagnosis of asthma within the 2 years prior to study entry * HIV-1 infected * Hepatitis C virus infected * Positive for hepatitis B surface antigen (HBsAg) * Abnormal blood or urine tests * Known immunodeficiency syndrome * Blood products, including immunoglobulin, within the 3 months prior to study entry * Immune globulin within 3 months of vaccination * Current smoker unwilling to stop smoking for the duration of the study * Participation in another investigational vaccine or drug trial within 30 days of vaccination or while participating in this study * Live vaccine within 4 weeks of vaccination * Killed vaccine within 2 weeks of vaccination * Previous immunization with PIV3 vaccine * Known hypersensitivity to any vaccine component * Other condition that, in the opinion of the investigator, would affect the participant's participation in the study * Work and/or personal responsibilities that involve caring for children less than 6 months of age or immunosuppressed individuals * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of vaccine-related reactogenicity events (REs) that occur during the acute monitoring phase of the study (Days 0 to 10 for adult and seropositive groups, Days 0 to 28 for seronegative groups) | Throughout study |
| Quantifying the amount of vaccine virus shed by each recipient | Throughout study |
| Determining the amount of serum antibody and mucosal antibody induced by the vaccine in each recipient | Throughout study |
Secondary
| Measure | Time frame |
|---|---|
| Determining the phenotypic stability of vaccine virus shed | Throughout study |
| Determining the number of vaccinated children and infants infected with rB/HPIV3 vaccine virus | Throughout study |
Countries
United States
Outcome results
None listed